HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated…
FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits for qualified…
FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits for qualified…
Transaction adds a validated antibody-discovery platform, Phase 2 candidate and royalty stream Company positioned as a leader in next-generation, end-to-end…
ATLANTA, GA / ACCESSWIRE / August 22, 2023 / The story of Lainie Jones, a cancer survivor from Fort Lauderdale,…
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Banner Health and nference, a science-first software company transforming healthcare by making biomedical data computable, today announced a…
New collaboration increases access to genetic testing and can help identify patients with a high-risk for breast cancerSALT LAKE CITY,…
REGAL Interim Analysis Expected by Late 2023/Early 2024 Enrollment Expected to be Completed in Q4 2023 NEW YORK, Aug. 22,…
Phase 1 trial expected to begin in early Q4 2023 VIP943 is Vincerx’ first candidate from next-generation ADC platform and…
Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8Significant progress with collaborators including selection of lead candidate…